PPT-Lenacapavir for Persons with Multidrug-Resistant HIV

CAPELLA Lenacapavir in Multidrug Resistant HIV CAPELLA Study Background Source SegalMaurer S et al N Engl J Med 202238617931803 Background Phase 3 randomized trial with oral and subcutaneous . Prevention of spread and c ontrol of MD s in health care setting are critical and urgent as the number of antibiotic available to treat these infections is extremely limited and development of new antibiotics is not forthcoming in the foreseeable fu United States and Puerto Rico. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention. Division of HIV/AIDS Prevention. National HIV Care Continuum. Used to gauge . progress towards national . P. Stogsdill, MD, FIDSA. Sept 2013. Bad bugs, No drugs. NO ESKAPE. E. nterococcus . faecium. S. taphylococcus . aureus. K. lebsiella. . pneumoniae. . C. lostridium. . difficile. A. cinetobacter. HIV/AIDS Surveillance System Highlights from the MN HIV Surveillance Report, 2015 Sexually Transmitted Diseases, HIV and Tuberculosis Section, Epidemiology and Surveillance Unit HIV/AIDS in Minnesota HIV/AIDS JAMA Theme Issue Media Briefing Copyright restrictions may apply. 2012 International AIDS Conference Sunday, July 22, 2012 HIV in Persons Born Outside the United States, 2007-2010 Prosser AT, Tang T, Hall HI. Global Fire Resistant Cable Market Size, Share, Industry Trends, Growth, Outlook & Analysis 2017-2027 By Insulation Material (Cross-Linked Polyethylene (XLPE), Polyvinyl Chloride (PVC), Low Smoke Zero Halogen (LSZH), Ethylene Propylene Rubber (EPR), and Others); By End-Use Industry (Building & Construction, Manufacturing, Energy, and Others); By Region, Competitive Market Share & Forecast meningitis in the United States, 1993-2005. Presenter: . Christopher Vinnard. World Epidemiology Congress 2011. Edinburgh, Scotland. Disclosures. No authors have financial or non-financial conflicts of interests that may be relevant to this presentation. HIV1 and slower to progress to AIDS.. Most cases are due to type1.. Modes of transmission. 1-sexual.. 2- perinatal.. 3-parenteral(occupational and intravenous drug injection).. 4- blood transfusion.. HIV/AIDS Surveillance System. HIV/AIDS Prevalence and . Mortality Report, . 2019. Introduction (I). These three introduction slides provide a general context for the data used to create this slide set. If you have questions about any of the slides, please refer to the . Pérez-Lago L, Lirola M, Navarro Y, Herranz M, Ruiz-Serrano M, Bouza E, et al. Co-infection with Drug-Susceptible and Reactivated Latent Multidrug-Resistant Mycobacterium tuberculosis. Emerg Infect Dis. 2015;21(11):2098-2100. https://doi.org/10.3201/eid2111.150683. . Teropavimab. (GS-5423) and . Zinlirvimab. (GS-2872) Dosed Every 6 Months in People with HIV. 1. UNC, Chapel Hill, NC; . 2. University of California, San Diego, San Diego, CA; . 3. CrofootMD Clinic and Research Center, Houston, TX; . Primary Care. David H. Spach, MD. Editor-in-Chief. , National HIV . Curriculum. Professor . of . Medicine. University . of . Washington. Seattle, Washington. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. John Stelling, MD, MPH, . jstelling@whonet.org. Brigham and Women’s Hospital, Harvard Medical School, Boston. WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. Webinar agenda. Comments on the WHONET Webinar series. Madeline Droney, PharmD. In it for the Long-Haul. Long-Acting Injectables in HIV Treatment. Conflict of Interest. The presenters report no conflict of interest. Review the treatment recommendations for human immunodeficiency virus (HIV) infection.